Renal Division, Department of Clinical Medicine, Faculty of Medicine, University of São Paulo, São Paulo, Brazil

Correspondence: Dr Roberto Zatz, Av. Dr. Arnaldo, 455 3-s/3342, CEP: 01246–903, São Paulo, SP Brazil. E-mail: rzatz@usp.br

Abstract

End-stage renal disease in Brazil: Epidemiology, prevention, and treatment. Brazil is one of the largest and most populous nations in the world, ranking among the 5 largest economies in the Americas and among the 15 largest economies in the world. However, Brazil is still plagued by social problems such as the persistence of poverty and immense deficiencies in its health system. Currently, there are approximately 390 patients on chronic renal replacement therapy (RRT) per million population, about one third the US prevalence, which suggests that end-stage renal disease is either underdiagnosed or undertreated. The epidemiology of renal disease in the small remaining native Brazilian population is largely unknown. However, it is likely that the prevalence of renal disease is low among at least 2 tribes: the Yanomamis in northern Brazil and the Xingu Indians in central Brazil. Sodium intake is very low, physical activity is intense, and the prevalence of hypertension and cardiovascular disease is negligible among these people, which stresses the potential pathogenic importance of so-called civilized habits. There is currently no conclusive evidence that African descendants or any other Brazilian ethnic minorities are especially vulnerable to renal disease. Access to RRT in Brazil is universal. However, because both the end-stage renal disease population and operational RRT costs are steadily increasing, the system may face severe limitations in the near future. Much effort is needed to limit the prevalence of renal disease, to detain or retard the progression of chronic nephropathies, and to ensure that high-quality RRT will remain available to all those who need it.